FDMT
Income statement / Annual
Last year (2024), 4D Molecular Therapeutics, Inc.'s total revenue was $37.00 K,
a decrease of 99.82% from the previous year.
In 2024, 4D Molecular Therapeutics, Inc.'s net income was -$160.87 M.
See 4D Molecular Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$37.00 K |
$20.72 M |
$3.13 M |
$18.04 M |
$13.61 M |
$6.99 M |
$14.13 M |
$5.79 M |
| Cost of Revenue |
$0.00
|
$97.10 M
|
$80.25 M
|
$61.36 M
|
$53.04 M
|
$38.72 M
|
$18.36 M
|
$13.57 M
|
| Gross Profit |
$37.00 K
|
-$76.37 M
|
-$77.12 M
|
-$43.32 M
|
-$39.43 M
|
-$31.73 M
|
-$4.23 M
|
-$7.78 M
|
| Gross Profit Ratio |
1
|
-3.69
|
-24.65
|
-2.4
|
-2.9
|
-4.54
|
-0.3
|
-1.34
|
| Research and Development Expenses |
$141.30 M
|
$97.10 M
|
$80.25 M
|
$61.36 M
|
$53.04 M
|
$43.86 M
|
$18.36 M
|
$13.57 M
|
| General & Administrative Expenses |
$46.58 M
|
$36.49 M
|
$32.91 M
|
$28.01 M
|
$17.24 M
|
$13.90 M
|
$6.17 M
|
$3.49 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$46.58 M
|
$36.49 M
|
$32.91 M
|
$28.01 M
|
$17.24 M
|
$13.90 M
|
$6.17 M
|
$3.49 M
|
| Other Expenses |
$0.00
|
-$97.10 M
|
-$80.25 M
|
-$61.36 M
|
-$53.04 M
|
-$38.72 M
|
-$2.00 K
|
-$40.00 K
|
| Operating Expenses |
$187.88 M
|
$36.49 M
|
$32.91 M
|
$28.01 M
|
$17.24 M
|
$19.03 M
|
$24.53 M
|
$17.06 M
|
| Cost And Expenses |
$187.88 M
|
$133.59 M
|
$113.16 M
|
$89.37 M
|
$70.28 M
|
$57.75 M
|
$24.53 M
|
$17.06 M
|
| Interest Income |
$27.05 M
|
$12.21 M
|
$2.57 M
|
$137.00 K
|
$152.00 K
|
$1.50 M
|
$850.00 K
|
$89.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$6.71 M
|
$4.20 M
|
$2.40 M
|
$1.52 M
|
$1.44 M
|
$1.00 M
|
$697.00 K
|
$626.00 K
|
| EBITDA |
-$181.14 M |
-$108.66 M |
-$107.63 M |
-$69.81 M |
-$55.22 M |
-$44.62 M |
-$9.70 M |
-$10.65 M |
| EBITDA Ratio |
-4895.57
|
-5.24
|
-34.4
|
-3.87
|
-4.06
|
-6.39
|
-0.69
|
-1.84
|
| Operating Income Ratio |
-5076.78
|
-5.45
|
-35.17
|
-3.95
|
-4.16
|
-7.27
|
-0.74
|
-1.95
|
| Total Other Income/Expenses Net |
$26.97 M
|
$12.03 M
|
$2.54 M
|
$16.00 K
|
-$29.00 K
|
$1.46 M
|
$848.00 K
|
$49.00 K
|
| Income Before Tax |
-$160.87 M
|
-$100.84 M
|
-$107.49 M
|
-$71.32 M
|
-$56.69 M
|
-$49.31 M
|
-$9.55 M
|
-$11.22 M
|
| Income Before Tax Ratio |
-4347.78
|
-4.87
|
-34.35
|
-3.95
|
-4.16
|
-7.06
|
-0.68
|
-1.94
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$89.00 K
|
| Net Income |
-$160.87 M
|
-$100.84 M
|
-$107.49 M
|
-$71.32 M
|
-$56.69 M
|
-$49.31 M
|
-$9.55 M
|
-$11.22 M
|
| Net Income Ratio |
-4347.78
|
-4.87
|
-34.35
|
-3.95
|
-4.16
|
-7.06
|
-0.68
|
-1.94
|
| EPS |
-2.98 |
-2.58 |
-3.12 |
-2.46 |
-2.12 |
-2 |
-0.76 |
-0.76 |
| EPS Diluted |
-2.98 |
-2.58 |
-3.12 |
-2.46 |
-2.12 |
-2 |
-0.76 |
-0.76 |
| Weighted Average Shares Out |
$53.94 M
|
$39.13 M
|
$32.35 M
|
$27.73 M
|
$26.68 M
|
$26.49 M
|
$12.52 M
|
$14.84 M
|
| Weighted Average Shares Out Diluted |
$53.94 M
|
$39.13 M
|
$32.35 M
|
$27.73 M
|
$26.68 M
|
$26.49 M
|
$12.52 M
|
$14.84 M
|
| Link |
|
|
|
|
|
|
|
|
